Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

  1. Slamon, D.J.
  2. Neven, P.
  3. Chia, S.
  4. Jerusalem, G.
  5. De Laurentiis, M.
  6. Im, S.
  7. Petrakova, K.
  8. Valeria Bianchi, G.
  9. Martín, M.
  10. Nusch, A.
  11. Sonke, G.S.
  12. De la Cruz-Merino, L.
  13. Beck, J.T.
  14. Ji, Y.
  15. Wang, C.
  16. Deore, U.
  17. Chakravartty, A.
  18. Zarate, J.P.
  19. Taran, T.
  20. Fasching, P.A.
Aldizkaria:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Argitalpen urtea: 2021

Alea: 32

Zenbakia: 8

Orrialdeak: 1015-1024

Mota: Artikulua

DOI: 10.1016/J.ANNONC.2021.05.353 GOOGLE SCHOLAR lock_openSarbide irekia editor

Objetivos de desarrollo sostenible

Datuen iturria: Scopus